|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 374.87 USD | -1.85% |
|
+0.03% | +6.94% |
| Capitalization | 83.31B 71.82B 66.86B 62.24B 116B 7,559B 125B 769B 303B 3,606B 312B 306B 13,166B | P/E ratio 2025 * |
14.8x | P/E ratio 2026 * | 15.3x |
|---|---|---|---|---|---|
| Enterprise value | 106B 91.42B 85.1B 79.23B 148B 9,622B 159B 979B 386B 4,589B 398B 389B 16,758B | EV / Sales 2025 * |
0.54x | EV / Sales 2026 * | 0.52x |
| Free-Float |
99.81% | Yield 2025 * |
1.78% | Yield 2026 * | 1.87% |
Last Transcript: Elevance Health, Inc.
| 1 day | -1.85% | ||
| 1 week | +0.03% | ||
| Current month | +6.94% | ||
| 1 month | +3.94% | ||
| 3 months | +7.26% | ||
| 6 months | +11.50% | ||
| Current year | +6.94% |
| 1 week | 365.1 |  | 383 |
| 1 month | 337.54 | | 383 |
| Current year | 345.01 | | 383 |
| 1 year | 273.71 | | 458.75 |
| 3 years | 273.71 | | 567.26 |
| 5 years | 273.71 | | 567.26 |
| 10 years | 114.85 | | 567.26 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gail Boudreaux
CEO | Chief Executive Officer | 65 | 20/11/2017 |
Mark Kaye
DFI | Director of Finance/CFO | 47 | 01/11/2023 |
Dustin Wilcox
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Ramiro Peru
CHM | Chairman | 70 | - |
Robert Dixon
BRD | Director/Board Member | 70 | 01/07/2011 |
Lewis Hay
BRD | Director/Board Member | 70 | 01/07/2013 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +1.50% | 3.22% | 26 M€ | |
| 0.00% | 2.07% | 5 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.85% | +0.03% | -3.70% | -22.39% | 84.88B | |
| -2.34% | -4.56% | -39.09% | -32.39% | 307B | |
| -2.06% | -4.12% | -4.35% | -13.37% | 74.24B | |
| -3.76% | -1.55% | -2.22% | -44.38% | 34.15B | |
| -3.22% | -2.49% | -27.55% | -40.62% | 23.23B | |
| -1.21% | +4.31% | -33.58% | -36.25% | 9.96B | |
| 0.00% | +7.40% | +61.87% | +79.14% | 4.5B | |
| +0.86% | -10.61% | +18.17% | -26.32% | 2.1B | |
| Average | -1.38% | +0.28% | -3.81% | -17.07% | 67.51B | |
| Weighted average by Cap. | -0.86% | -0.98% | -24.76% | -28.43% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 198B 170B 159B 148B 275B 17,932B 296B 1,824B 719B 8,553B 741B 726B 31,232B | 204B 176B 164B 152B 283B 18,489B 305B 1,881B 742B 8,819B 764B 748B 32,203B |
| Net income | 5.69B 4.9B 4.56B 4.25B 7.91B 516B 8.51B 52.51B 20.7B 246B 21.33B 20.89B 899B | 5.34B 4.61B 4.29B 3.99B 7.43B 485B 8B 49.32B 19.45B 231B 20.03B 19.62B 844B |
| Net Debt | 22.73B 19.6B 18.24B 16.98B 31.62B 2,063B 34.02B 210B 82.75B 984B 85.25B 83.49B 3,592B | 23.03B 19.85B 18.48B 17.21B 32.04B 2,090B 34.47B 213B 83.83B 997B 86.36B 84.58B 3,639B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 374.87 $ | -1.85% | 1,068,700 |
| 15/01/26 | 381.93 $ | +2.44% | 1,531,154 |
| 14/01/26 | 372.84 $ | +0.58% | 1,144,042 |
| 13/01/26 | 370.68 $ | -1.14% | 820,043 |
| 12/01/26 | 374.97 $ | +0.57% | 984,673 |
Delayed Quote Nyse, 17 January 2026 at 08:00 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ELV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition